FILTER

Refine your search with the following facets to narrow down your results.

13 Current news of Action Pharma

Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

07-May-2012 - Abbott and Action Pharma A/S announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in ...

Abbott acute kidney injury

Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury demonstrates positive top-line results

28-Sep-2011 - Action Pharma A/S announced positive top-line results for its phase IIb AP214 trial in patients undergoing major cardiac surgery. The study demonstrated that AP214 is safe, reduces kidney injury, and improves long-term (90 days) outcomes on a composite end point (death, dialyses and kidney ...

acute kidney injury cardiothoracic surgery phase IIb studies

Last patient completes last visit in Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

09-Aug-2011 - The final patient has performed the last visit of the study period in Action Pharma’s US and Denmark based phase IIb study. Treatment with AP214 is designed to investigate whether acute kidney injury can be prevented in patients undergoing major cardiac surgery – a serious unmet medical need with ...

acute kidney injury cardiothoracic surgery phase IIb studies

Action Pharma completes dosing in phase IIb clinical trial with AP214 to prevent acute kidney injury associated with cardiac surgery

10-May-2011 - Action Pharma A/S has completed dosing in a phase IIb clinical trial with its leading development candidate, AP214. Efficacy and safety data are expected during the third quarter of 2011. AP214 is being developed for protection of kidney injury in patients undergoing cardiac surgery under ...

acute kidney injury phase IIb studies

Action Pharma initiates phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

10-Nov-2010 - Action Pharma A/S has administered the first dose to the first patient in a phase IIb clinical trial being undertaken in the USA and Denmark with its leading drug candidate AP214. This follows the positive results obtained on safety, tolerability and efficacy in the phase IIa clinical trial ...

acute kidney injury cardiothoracic surgery clinical trials +3

Action Pharma obtains positive results in a phase II clinical trial with AP214

15-Sep-2010 - Action Pharma A/S has obtained positive safety, tolerability and efficacy results in the second phase II clinical trial (CS005) with its leading development candidate, AP214. AP214 is being developed for protection of acute kidney injury (AKI) in patients undergoing cardiac surgery under ...

acute kidney injury cardiothoracic surgery clinical trials +1

Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214

09-Jun-2010 - Action Pharma A/S obtained encouraging preliminary blinded results in the second phase II clinical trial (named CS005) with its lead development candidate, AP214. AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as ...

acute kidney injury cardiothoracic surgery clinical trials +2

Action Pharma completes EUR 5 million financing round to advance its lead project AP214

04-Jun-2010 - Action Pharma A/S has completed an internal financing round of EUR 5 million which is dedicated to advance the Company’s ongoing phase 2a studies, and the initiation of a phase 2b study, for AP214. AP214 is being developed for the protection of acute kidney injury in patients undergoing cardiac ...

acute kidney injury cardiothoracic surgery Life Sciences

Action Pharma completes dosing in phase II clinical trial with AP214 to prevent acute kidney injury

30-Mar-2010 - Action Pharma A/S has completed dosing in the second phase II clinical trial with its leading development candidate, AP214. Interim efficacy data are expected June 2010. AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary ...

acute kidney injury cardiothoracic surgery clinical trials +5

Action Pharma focuses its strategy and appoints a new CEO

25-Mar-2010 - The Board of Directors of Action Pharma has decided to focus the Company’s strategy on partnering of its lead projects and to explore the opportunity of strengthening the Company through M&A or consolidation. To drive this process the Board of Directors has appointed Ingelise Saunders as new CEO ...

Denmark Novo Nordisk